Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$15 Mln
Revenue (TTM)
$0 Mln
Net Profit (TTM)
$0 Mln
ROE
0.2 %
ROCE
-- %
P/E Ratio
5.3
P/B Ratio
1
Industry P/E
--
EV/EBITDA
0.2
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$0.1
Face value
--
Shares outstanding
11,696,100
CFO
$-409.16 Mln
EBITDA
$-426.39 Mln
Net Profit
$-441.38 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Synlogic (SYBX)
| -14.8 | 5.6 | -8.2 | -19.9 | -59.0 | -48.6 | -- |
|
BSE Sensex*
| 5.7 | 1.2 | 6.1 | 7.0 | 16.2 | 18.9 | 11.6 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|---|---|---|---|---|---|---|---|
|
Synlogic (SYBX)
| -63.3 | -66.2 | -68.6 | 12.0 | -16.3 | -63.2 | -27.6 |
|
S&P Small-Cap 600
| 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 | -9.7 |
|
BSE Sensex
| 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 | 5.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Synlogic (SYBX)
|
1.2 | 14.7 | 0.0 | 1.5 | -- | 11.4 | 5.3 | 1.0 |
| 50.0 | 7,821.1 | 1,208.8 | 131.7 | 13.4 | 6.3 | 60.1 | 3.9 | |
| 128.3 | 8,303.1 | 562.1 | -155.7 | -19.3 | -47.5 | -- | 24.2 | |
| 148.4 | 7,238.7 | 4,022.6 | -31.6 | 3.7 | -1.1 | -- | 2.3 | |
| 51.2 | 9,911.0 | 2,828.1 | -1,019.8 | -36.2 | -36.4 | -- | 4.2 | |
| 45.7 | 11,827.4 | 2,298.9 | 643.6 | 35.4 | 29.2 | 19.8 | 5.2 | |
| 53.9 | 6,506.1 | 1,084.3 | 485.4 | 57.0 | 103.8 | 14 | 13.5 | |
| 315.3 | 8,891.5 | 2,156.6 | 416.4 | 21.2 | 56.5 | 23.6 | 15.0 | |
| 26.8 | 9,927.7 | 3,159.0 | -3,357.0 | -76.7 | -30.5 | -- | 1.0 | |
| 128.2 | 12,449.9 | 2,412.6 | 305.8 | 20.5 | 11.6 | 42.8 | 4.9 |
Synlogic, Inc., a biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618 for the treatment of phenylketonuria; SYNB1353, an orally... administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and Ginkgo Bioworks, Inc. Synlogic, Inc. is based in Winchester, Massachusetts. Address: PO Box 30, Winchester, MA, United States, 01890 Read more
Principal Executive Officer & COO
Mr. Antoine Awad
Principal Executive Officer & COO
Mr. Antoine Awad
Headquarters
Winchester, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Synlogic Inc (SYBX) stood at $ 23 Mln as on 31-Mar-25
The share price of Synlogic Inc (SYBX) is $1.19 (NASDAQ) as of 24-Jun-2025 16:00 EDT. Synlogic Inc (SYBX) has given a return of -58.95% in the last 3 years.
Synlogic Inc (SYBX) has a market capitalisation of $ 15 Mln as on 24-Jun-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Synlogic Inc (SYBX) is 1.05 times as on 24-Jun-2025, a 62% discount to its peers’ median range of 2.79 times.
The P/E ratio of Synlogic Inc (SYBX) is 5.32 times as on 24-Jun-2025.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Synlogic Inc (SYBX) and enter the required number of quantities and click on buy to purchase the shares of Synlogic Inc (SYBX).
Synlogic, Inc., a biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618 for the treatment of phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and Ginkgo Bioworks, Inc. Synlogic, Inc. is based in Winchester, Massachusetts. Address: PO Box 30, Winchester, MA, United States, 01890
The CEO & director of Mr. Antoine Awad. is Synlogic Inc (SYBX), and CFO & Sr. VP is Mr. Antoine Awad.
There is no promoter pledging in Synlogic Inc (SYBX).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,260
|
|
|
1,128
|
|
|
991
|
|
|
988
|
|
|
870
|
|
|
829
|
|
|
809
|
|
|
742
|
|
|
664
|
| Synlogic Inc. (SYBX) | Ratios |
|---|---|
|
Return on equity(%)
|
11.43
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Synlogic Inc (SYBX) was $0 Mln.
$0.02
(
